Gynecological cancers include cancers of the ovary, vulva, cervix and endometrium (body of the uterus)

Lacassagne offers a comprehensive and personalized care, with shortened deadlines in all phases of the care path, ranging from screening to oncogenetic analysis, including surgery, chemotherapy, targeted therapies, radiotherapy brachytherapy, hormone therapy; as well as support care.

Endometrial cancer is the 4th leading cause of cancer in women. After breast cancer, it is the most common gynecological cancer. It usually affects women after menopause, the average age of diagnosis is 68.

Lacassagne has set up diagnostic hysteroscopy consultation for patients with suspected endometrial cancer (either menopausal patients who have bleeding or patients who have been found to have thickened endometrium during ultrasound as part of the follow-up of their cancer). Consultation involves visualizing the inside of the uterine cavity using a flexible hysteroscope and possible targeted biopsies. The hysteroscopy is done on Monday or Tuesday and the patient is reviewed in consultation at the end of the week with the results, ie diagnosis in 3 days.

Cervical cancer is the 12th leading cause of cancer in women. Its main cause is persistent sexually transmitted viral infection to the human papillomavirus or HPV (human papillomavirus).

Regular Pap smear screening for precancerous lesions has halved the number of new cases, as well as the number of deaths, over the last 20 years. Vaccination of young girls against the main types of HPV is a complementary way of acting against this cancer.


Coelioscopie 3D

Over the last decades, new, less invasive surgical techniques have been developed, such as laparoscopy which allows surgery to be performed without making a large incision by introducing an optic through the navel.

In parallel, cancer surgery offers more personalized treatment and better quality of life for women with cancer whose prognosis has improved in recent decades.

3D vision laparoscopy recreates on screen the actual conditions , thus improving surgical efficiency and precision.

This technology can benefit patients with cancer of the cervix or uterus as well as some early forms of ovarian cancer.



Pr Jean-Marc Ferrero
Dr Delphine Borchiellini
Dr Anne Creisson
Dr Philippe Follana
Dr Véronique Mari
Dr Jérôme Barrière
Dr Rémy Largillier
Dr Véronique Mari (Onco-genetics)


Pr Emmanuel Barranger
Dr Yves Fouché


Dr Marie-Eve Chand Fouché
Dr Alexander Falk
Pr Jean-Michel Hannoun-Lévi
Dr Daniel Lam Cham Kee
Dr Shakeel Sumodhee

All information brochures are available here